All News

A recent study found that continuous glucose monitors could help improve patient comfort, reduce resource use, and improve outcomes.

Researchers explored how social media advertising of lifestyle drugs contributes to the normalization of use for semaglutide, testosterone, and sildenafil.

George Van Antwerp, MBA, discusses how the role of the pharmacist will evolve with the integration of precision medicine into the health systems setting.

In an Axios analysis of US Senate lobbying disclosures from the past year, researchers explored the ongoing trends of how certain industries distribute influence among legislators.

Jade Ranger, PharmD, discusses her experiences during the COVID-19 pandemic as one of the first pharmacies to receive the COVID-19 vaccines.

Jeffery Goad, PharmD, MPH, president of the National Foundation for Infectious Diseases, reflects on the COVID-19 pandemic 5 years later.

The new approval is an oral suspension for patients with hypertension and left ventricular hypertrophy and for the treatment of diabetic nephropathy.

A conversation with Lydia Newsom, PharmD, clinical associate professor of pharmacy practice at Mercer University College of Pharmacy.

Pharmacists are resilient, community-focused professionals who played a pivotal role in navigating the unprecedented challenges of the COVID-19 pandemic.

The top reported barriers to providing buprenorphine included regulatory and administrative, operational and attitudinal, and patient-related challenges.

On both an individual and societal level, researchers explored how social, cultural, and ethnic determinants impact the treatment and management of obesity.

As pharmacists move away from opioids in pain management, researchers present the use of supplemental OTC products to assist patients’ acute pain.

Because of their accessibility in the community, pharmacists can help to deliver balanced and individualized services and address social determinants of health.

A conversation with Nicole Cieri-Hutcherson, PharmD, BCPS, MSCP, FCCP, clinical associate professor at University at Buffalo.

The most commonly reported symptoms of long COVID include neurological, muscular, respiratory, and psychological.

Using a novel pharmacy vulnerability index, researchers identified US regions at the most risk of becoming pharmacy deserts.

Tirzepatide and semaglutide show long-term health care cost savings but, the high cost of the medications offset the savings.

Among various weights and diabetes diagnoses, researchers explored the differences in patients’ food perceptions when considering weight management and appetite.

Among the drugs presented, Biktarvy and lenacapavir, teropavimab, and zinlirvimab (LTZ) demonstrate rates of suppression of HIV, and vesatolimod is well tolerated.

George Van Antwerp, MBA, senior vice president of Product Innovation and Strategic Planning at Prime Therapeutics, discusses how pharmacists can help patients decide which digital tools are best for them.

A new report from the American Economic Liberties Project presents the continued challenges pharmacies face since Congress’ failure to pass PBM reform at the end of 2024.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discussed the common trends in GLP-1 use she’s seen amongst her patients as well as her extensive experience working with this medication class.

These findings challenge the common assumption that older adults might struggle to use more advance medical devices.

This year’s meeting will take place from March 21 to 24 in Nashville, Tennessee.

Additional data shows that an investigational drug, given every 4 months with Apretude, kept viral levels suppressed for patients who were already on stable treatment.

These findings are shared as late-breaking data at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI) being held in San Francisco, California.

Researchers compared changes in diet quality and waist-to-hip ratio during midlife with that of hippocampal connectivity and cognitive function in later life.

Approximately, 62% of respondents stated that the number of active drug shortages could potentially increase by more than 25% within the next 5 years.